Login to Your Account



Full-'Spectrum' light at the end of the tunnel?

By Randy Osborne
Staff Writer

Wednesday, December 31, 2014

With a new drug application recently filed for Captisol-enabled melphalan in multiple myeloma and SPI-2012, a long-acting granulocyte stimulating factor said to have billion-dollar potential, going into phase III trials next year for chemotherapy-induced neutropenia, Spectrum Pharmaceuticals Inc.'s only cloud on the horizon seems to be the patent battle over the folate analog Fusilev in cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription